Eli Lilly Gets PTAB To Review More Teva IP On Migraine Drug
The Patent Trial and Appeal Board has agreed to review the validity of a patent on Teva's migraine treatment drug Ajovy, marking the latest development in Teva's battle with Eli Lilly...To view the full article, register now.
Already a subscriber? Click here to view full article